Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort

• Autor(a) principal: Ruben, Brandão
• Data de Publicação: 2018
• Outros Autores: Rute, Marcelino, Goncalves, Maria de Fátima, Diogo, Isabel, Carvalho, A P, Cabanas, Joaquim, Costa, Inês, Brogueira, Pedro, Ventura, F, Miranda , Ana Cláudia, Mansinho, Kamal, Gomes, P
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/116851
• topic: Direct-acting antivirals; Hepatitis C virus; NS5A; NS5B; Resistance-associated substitutions; SDG 3 - Good Health and Well-being

This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).